Navigation Links
ERT Reports First Quarter 2009 Results
Date:4/30/2009

PHILADELPHIA, April 30 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERES), a leading provider of centralized ECG, eClinical technology, ePRO and other services to the biopharmaceutical, medical device, and related industries, announced today results for the first quarter of 2009. Unless otherwise noted, all comparative numbers refer to changes from the same period a year ago.

Highlights of the first quarter were:

  • Quarterly net revenue was $23.8 million for the first quarter of 2009 compared to $33.7 million a year ago.
  • Gross margin percentage was 50.4% in the first quarter of 2009 compared to 52.5% a year ago.
  • Operating income margin percentage was 14.0% in the first quarter of 2009 compared to 25.2% a year ago.
  • ERT's tax rate was 40.1% in the first quarter of 2009 compared to 35.6% a year ago.
  • Net income was $2.1 million for the first quarter of 2009 compared to $5.7 million a year ago.
  • Diluted net income per share was $0.04 in the first quarter of 2009 compared to $0.11 a year ago.
  • New bookings were $31.2 million in the first quarter of 2009 compared to $50.1 million a year ago.
  • Total expenses were $20.4 million in the first quarter of 2009, compared to $25.2 million a year ago.
  • Cash flow from operations in the first quarter of 2009 was $9.1 million, compared to $7.6 million a year ago.
  • Cash, cash equivalents and investments totaled $65.6 million at March 31, 2009 compared to $66.4 million at December 31, 2008.
  • ERT purchased 1,965,452 shares of its common stock at an average price of $5.05 under its approved stock repurchase program in the first quarter of 2009 at a total cost of $10.0 million.
  • Backlog w
    '/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. CryoLife Reports Record First Quarter Revenues of $26.7 Million
2. Caliper Life Sciences Reports First Quarter 2009 Results
3. Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets
4. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Telik Reports Preclinical Results at AACR Annual Meeting
7. PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
8. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
9. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
10. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
11. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... LEXINGTON, Mass. , April 21, 2015 ... company developing transformative pharmaceutical products for subcutaneous ... its pivotal trial of its investigational proprietary ... treatment of edema associated with congestive heart ... development, scPharmaceuticals is developing a proprietary patch ...
(Date:4/21/2015)... Thornton Cleveleys (UK) (PRWEB) April 21, 2015 ... PEEK* technology and its clinical applications will ... Meeting. Participants include engineers, scientists, regulators and ... worldwide. The meeting is sponsored by Invibio ... PEEK polymer-based biomaterials, a specialist in manufacturing ...
(Date:4/20/2015)... MENLO PARK, Calif. , April 20, ... DMPI) (DelMar and the Company), a biopharmaceutical company ... in new orphan drug indications, today announced promising ... of the American Association for Cancer Research ... lead product candidate VAL-083 (dianhydrogalactitol) to ...
(Date:4/20/2015)... 2015  Eli Lilly and Company (NYSE: LLY ... cancer therapies, reflecting Lilly,s diverse oncology pipeline, during the ... held April 18-22 in Philadelphia , ... is the theme of this year,s AACR meeting and ... its portfolio of therapies that accelerate the pace and ...
Breaking Biology Technology:scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 32nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6
... RICHARDSON, Texas, Aug. 21 Zyvex Labs today ... company was started by Rob,Burgess, PhD, former Vice ... Gareth Hughes, PhD, former Group Leader of Life ... the application of nanotechnology in Life,Sciences. The company ...
... BOSTON and THE WOODLANDS, Texas, Aug. 21 ... presented data today,describing the structure-activity relationship (SAR) ... LX1031 and other compounds,under evaluation by the ... (IBS) and other gastrointestinal disorders. LX1031 is ...
... PITTSBURGH, Aug. 21 The Pittsburgh Life ... life,sciences industry on a fast track for growth, ... $450,000 in three companies: Applied Computational,Technologies, Separation Design ... to identifying and making investments in promising,life sciences ...
Cached Biology Technology:NanoMed, Inc. Spins Out of Zyvex Labs 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 2The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 3
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... the buzzword "nano" - cancer detection using nanoparticles and ... cancers is one of the most important parts of ... and determination,of the most appropriate treatment. And an essential ... there has been lymphatic spread. Current,methods include surgical removal ...
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... drugs that keep the HIV-virus infection from progressing to ... disturbances in some patients. The finding of a Mayo ... The Lancet. , In collaboration with colleagues from the ... University of Minnesota, Minneapolis, and University of Wisconsin, Madison, ...
Cached Biology News:Imaging Lymph Nodes with Nanoparticles 2GATA: a graphic alignment tool for comparative sequence analysis 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 3
... Polyclonal Antibody, Unconjugated ... a dilution of 1/100. IP: Use ... Use at an assay dependent dilution. ... tested in other applications. Optimal ...
Membrane Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... analysis in a modern flow cytometer, a ... are differentially labeled with fluorescent probes. However, ... used for cell labeling are broader than ... flow cytometers filters. Thus, the fluorescence signal ...
... Shaker ,Product Information ... a high quality, general purpose shaker with economical ... other models in the line, the Orbit LS ... panel. Electronic controls are utilized for setting speed ...
Biology Products: